Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: A randomized, double-blind, placebo controlled trial

Pediatric Pulmonology

Volumn 46, Issue 2, 2011, Pages 111-118

  Ballard, Hubert O ^a   Shook, Lori A ^a   Bernard, Philip ^a   Anstead, Michael I ^a   Kuhn, Robert ^a   Whitehead, Vicki ^a   Grider, Deb ^a   Crawford, Timothy N ^a   Hayes, Don ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

azithromycin; bronchopulmonary dysplasia; Ureaplasma

Indexed keywords

AZITHROMYCIN; PLACEBO; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM DETECTION; BIRTH WEIGHT; CHEMOPROPHYLAXIS; CHILDHOOD MORTALITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRACHEAL ASPIRATION PROCEDURE; UREAPLASMA; UREAPLASMA PARVUM; UREAPLASMA UREALYTICUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INCIDENCE; ISOLATION AND PURIFICATION; MORTALITY; NEWBORN; UREAPLASMA INFECTION; VERY LOW BIRTH WEIGHT;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHOPULMONARY DYSPLASIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; MALE; RESPIRATION, ARTIFICIAL; UREAPLASMA; UREAPLASMA INFECTIONS;

EID: 79251508642     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21352     Document Type: Article

References (37)

1. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K,. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 1353-1360.
2. Northway WH, Jr., Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm RL, Brown BW, Jr., Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990; 323: 1793-1799.
3. Baraldi E, Filippone M,. Chronic lung disease after premature birth. N Engl J Med 2007; 357: 1946-1955.
4. Greenough A,. Long-term pulmonary outcome in the preterm infant. Neonatology 2008; 93: 324-327.
5. Bhandari A, Panitch HB,. Pulmonary outcomes in bronchopulmonary dysplasia. Semin Perinatol 2006; 30: 219-226.
6. Jobe AH, Ikegami M,. Antenatal infection/inflammation and postnatal lung maturation and injury. Respir Res 2001; 2: 27-32.
7. Jobe AJ,. The new BPD: an arrest of lung development. Pediatr Res 1999; 46: 641-643.
8. Bancalari E, Claure N, Sosenko IR,. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 2003; 8: 63-71.
9. Watterberg KL, Demers LM, Scott SM, Murphy S,. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97: 210-215.
10. Remington JS, Klein JO,. Infectious: diseases of the fetus and newborn infant. Philadelphia: W.B. Saunders; 2001. xiv, 1507 pp.
11. Schelonka RL, Katz B, Waites KB, Benjamin DK, Jr., Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J 2005; 24: 1033-1039.
12. Waites KB, Katz B, Schelonka RL,. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18: 757-789.
13. Viscardi RM, Hasday JD,. Role of ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence. Pediatr Res 2009; 65 (5 pt2): 84R-90R.
14. Baier RJ, Loggins J, Kruger TE,. Failure of erythromycin to eliminate airway colonization with ureaplasma urealyticum in very low birth weight infants. BMC Pediatr 2003; 3: 10.
15. Jonsson B, Karell AC, Ringertz S, Rylander M, Faxelius G,. Neonatal Ureaplasma urealyticum colonization and chronic lung disease. Acta Paediatr 1994; 83: 927-930.
16. Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW,. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Archives of disease in childhood 1998; 78: F10-F14. (Pubitemid 28241973)
17. Waites KB, Sims PJ, Crouse DT, Geerts MH, Shoup RE, Hamrick WB, Duffy LB, Cassell GH,. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection. Pediatr Infect Dis J 1994; 13: 287-293.
18. Ballard HO, Anstead MI, Shook LA,. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007; 8: 41.
19. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J,. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
20. Pirzada OM, McGaw J, Taylor CJ, Everard ML,. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. J Cyst Fibros 2003; 2: 69-71.
21. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR,. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24: 1440-1443.
22. Cakan H, Polat E, Kocazeybek B, Ocal P, Cepni I, Aslan M, Salihoglu F, Altas K,. Assessment of antibiotic susceptibility of Ureaplasma urealyticum from prostitutes and outpatient clinic patients using the E-test and agar dilution method. Chemotherapy 2003; 49: 39-43.
23. Matlow A, Th'ng C, Kovach D, Quinn P, Dunn M, Wang E,. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. Antimicrob Agents Chemother 1998; 42: 1290-1292.
24. Cheah FC, Winterbourn CC, Darlow BA, Mocatta TJ, Vissers MC,. Nuclear factor kappaB activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and Ureaplasma urealyticum colonization. Pediatr Res 2005; 57: 616-623.
25. Groneck P, Schmale J, Soditt V, Stutzer H, Gotze-Speer B, Speer CP,. Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease. Pediatr Pulmonol 2001; 31: 331-338.
26. Kotecha S, Hodge R, Schaber JA, Miralles R, Silverman M, Grant WD,. Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants. Pediatr Res 2004; 55: 61-68.
27. Patterson AM, Taciak V, Lovchik J, Fox RE, Campbell AB, Viscardi RM,. Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J 1998; 17: 321-328.
28. Li YH, Chen M, Brauner A, Zheng C, Skov Jensen J, Tullus K,. Ureaplasma urealyticum induces apoptosis in human lung epithelial cells and macrophages. Biol Neonate 2002; 82: 166-173.
29. Moss TJ, Nitsos I, Ikegami M, Jobe AH, Newnham JP,. Experimental intrauterine Ureaplasma infection in sheep. Am J Obstet Gynecol 2005; 192: 1179-1186.
30. Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, Eydelman R, Strande L, Leone P, Rahman I,. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007; 62: 483-488.
31. Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, Galovic R, Glojnaric I, Manojlovic Z, Munic V, Novak-Mircetic R, Pavicic-Beljak V, Sucic M, Veljaca M, Zanic-Grubisic T, Parnham MJ,. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277-289.
32. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M,. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-163.
33. Jaffe A, Bush A,. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31: 464-473. (Pubitemid 32523640)
34. Tamaoki J,. The effects of macrolides on inflammatory cells. Chest 2004; 125: 41S-50S, quiz51S.
35. Wales D, Woodhead M,. The anti-inflammatory effects of macrolides. Thorax 1999; 54: S58-S62.
36. Heggie AD, Jacobs MR, Butler VT, Baley JE, Boxerbaum B,. Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants. J Pediatr 1994; 124: 956-961.
37. Bowman ED, Dharmalingam A, Fan WQ, Brown F, Garland SM,. Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants. Pediatr Infect Dis J 1998; 17: 615-620.